Research.Patient.info

Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingPhase I and Phase II (Integrated)- Other
A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02)
This study is for people with a type of blood disorder called higher-risk myelodysplastic syndrome (MDS) who haven't had treatment yet. It tests a new drug called ALX148 with an existing medicine, azacitidine, to see if it's safe and helps improve the condition.
Spain